Clinical trial
A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD)
NCT00414206 is registered in ClinicalTrials.gov with CoMentis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD)
- Lead sponsor
- CoMentis
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 31, 2007
- Completion date
- September 30, 2009
- Enrollment
- 343 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.